359 related articles for article (PubMed ID: 12581971)
1. [Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer].
Zheng H; He BF; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):165-6. PubMed ID: 12581971
[TBL] [Abstract][Full Text] [Related]
2. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
Huang F; Wang XL; Yang L; Yin BX; Geng Y; Li TT
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):370-2. PubMed ID: 18394347
[TBL] [Abstract][Full Text] [Related]
5. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
6. [Relation between the level of TPS, NSE, CEA and beta2-mG in the serum and the biological behavior of small cell lung cancer].
Chen MS; Xu Y; Ma J; Wu CG; Hao XK; Lu BB; Liu T
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Aug; 23(8):751-3. PubMed ID: 17618570
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
Chen W; Luo RC; Fan WW; Ma SD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
11. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
12. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
13. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
Ratto GB; Mereu C; Rovida S
Panminerva Med; 1993 Dec; 35(4):186-92. PubMed ID: 8202329
[TBL] [Abstract][Full Text] [Related]
14. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
15. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
Wu Y; Wu Y; Wang L; Qu L
Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
[TBL] [Abstract][Full Text] [Related]
16. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
17. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
18. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
19. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
